Smart delivery for superior treatment.

For patients, worldwide.

Pharmaceutical company AMW provides patients with biodegradable drug delivery systems for improved and cost-effective therapies. With state-of-the-art production facilities in Germany, the entire pharmaceutical value chain is covered. Our employees, with their individual ideas and skills, are crucial to our success.

More about us

Our focus

Research & Development

Cutting-edge technology and know-how in extrusion: AMW’s technology platform as the basis for our growing development pipeline of drug delivery systems

Learn more

Products

Our implants goserelin and leuprorelin for the treatment of hormone-sensitive tumors

Learn more

Services

We support our pharma and biotech partners locally and globally – from technology collaboration to contract development

Learn more

We cover the entire value chain for drug delivery systems – from (co-)development and manufacturing to commercialization or out-licensing.

Careers at AMW

Temporary staff (m/f/d) for production full time

To the job offer

Production worker (m/f/d)

To the job offer

Team Leader for IT (m/f/d)

To the job offer

All job ads

Latest News

9. August 2023

AMW Receives first Notified Body Opinion by TÜV SÜD and Lays the Foundation for Further Approvals of Goserelin in the EU

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has achieved a key milestone in opening new markets within the European Union (EU) and beyond with the final report of the first Notified Body Opinion (NBO) for its goserelin implant.

11. April 2023

AMW reports financial results for fiscal 2022 and updates on corporate performance

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today released its financial results for the year ended December 31, 2022. AMW reported record consolidated sales for 2022 of €22.8 million and achieved operating profitability for the first time in the company’s history. The company also reported that Philipp Karbach will assume the position of chief executive officer (CEO) effective June 1, 2023, as Dr. Konstantin Petropoulos has decided to step down as CEO of AMW GmbH effective May 31, 2023, to pursue new opportunities. Philipp Karbach joined AMW in 2016, most recently in his role as Chief Operating Officer (COO) and Chief Financial Officer (CFO).

7. February 2023

AMW Appoints Professor Olivia Merkel to the Scientific Advisory Board

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today announced the appointment of Prof. Dr. Olivia Merkel, Professor of Drug Delivery at the Faculty of Chemistry and Pharmacy of Ludwig-Maximilians-Universität (LMU) Munich, as a member of its Scientific Advisory Board (SAB). Prof. Merkel is an internationally recognized expert in novel and targeted drug delivery systems, including RNA delivery systems. Her appointment will strengthen AMW’s scientific expertise in sustained-release delivery systems, such as biodegradable implants, and contribute to the company’s strategic development plans. With her appointment, Prof. Merkel succeeds Prof. Dr. Gerhard Winter, who will step down from his position on the Scientific Advisory Board.

All News & Events